Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

NCT ID: NCT04586543

Last Updated: 2020-10-14

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 110 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-05-18
• Study Completion Date: 2025-02-01

Brief Summary

The objective of this clinical study is to evaluate the effectiveness and safety of selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy - among patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma.

Detailed Description

Prostate cancer is one of the leading cause of cancer death among males worldwide. The objective of this phase II, randomized, controlled, open label study is to evaluate the effectiveness and safety of MAO-B (Monoamine oxidases-B) inhibitor selegiline plus docetaxel therapy. Patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma are randomly divided into two groups. One group (control arm) receives docetaxel (75 mg/m2 IV every 3 weeks for maximum of 12 cycles). Another group (experimental arm) receives docetaxel (75 mg/m2 IV every 3 weeks for maximum of 12 cycles) plus selegiline (daily 10 mg tablet). Patients are followed up for 36 months or until the end of the trial, death or withdraw from this study due to other reasons. The primary endpoint of this study is the proportion of patients without progression at month 9. The secondary endpoint is proportion of patients without progression at month 12/18, progression-free survival, overall survival, duration of PSA response, radiological response rate, PSA response rate, health-related quality of life and safety.

Conditions

Metastatic Castration-resistant Prostate Cancer; Adenocarcinoma of the Prostate

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Selegiline+ Docetaxel

Selegiline and plus Docetaxel

Group Type: EXPERIMENTAL

Selegiline

Intervention Type: DRUG

10 mg selegiline tablet per day

Docetaxel

Intervention Type: DRUG

75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles

Docetaxel

Docetaxel

Group Type: ACTIVE_COMPARATOR

Docetaxel

Intervention Type: DRUG

75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles

Interventions

Selegiline

10 mg selegiline tablet per day

Intervention Type: DRUG

Docetaxel

75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age 18 years or older male patients,

2. Histologically or cytologically confirmed prostate adenocarcinoma

3. Radiologically confirmed metastatic disease,

4. Eligibility to receive oral therapy,

5. Suitable for docetaxel therapy,

6. Patients with castration-resistant prostate carcinoma who eligible to first-line docetaxel therapy or patients with castration-resistant prostate cancer who progressed after second-generation hormone therapy (abiraterone or enzalutamide) with pre-chemotherapy indication and eligible to second-line docetaxel therapy

7. At least 4 weeks has elapsed between the last antiandrogenic therapy and the inclusion (at least 6 weeks in case of bicalutamide),

8. Planned docetaxel treatment,

9. Eastern Cooperative Oncology Group (ECOG) performance status: ≤ 2,

10. Estimated life expectancy of more than 12 weeks,

11. Adequate analgesic therapy as required;

12. Patients must be able to follow the diet and medical instructions,

13. Use of effective contraception in men of childbearing age,

14. Provision of signed, written information consent

Exclusion Criteria

1. De novo metastatic patients who needs immediate docetaxel therapy;

2. Within 4 weeks prior to randomisation, the patient has received other study medication or failed to recover from any adverse events caused from a previously administered study drug

3. ≥ Grade 2 anticancer therapy-related toxicity (except alopecia),

4. Has had radiotherapy or immunotherapy within 4 weeks prior to treatment,

5. Has had a surgery within 4 weeks prior to treatment,

6. Known or suspected brain metastasis (stable patients with locally treated, asymptomatic brain metastases are not excluded),

7. Inadequate laboratory function:

1. Absolute neutrophil count <1.5 x 109 /L (1,500 per mm3),

2. Platelet count < 100 x 109 /L (100 000 per mm3),

3. Hemoglobin ≤9.0 g/dL,

4. Serum bilirubin > ULN,

5. AST or ALT

i.>2.5 x ULN in patient without liver metastases, ii.>5x ULN in patients with liver metastases.

8. Cardiological status:

1. Uncontrolled hypertension (BP ≥ 150/95 with hypertension treatment)

2. Heart failure (NYHA III or higher),

3. Current or former diagnosis of cardiomyopathy,

4. LVEF ≤ 50%,

5. Atrial fibrillation with >100bpm pulse,

6. Unstable ischemic heart disease (myocardial infarction within 6 months or angina that require more than one nitrate therapy each week).

9. Other uncontrolled or severe systemic disease, active infection, hepatitis B, hepatitis C, HIV,

10. Uncontrolled seizure disorder,

11. Active gastric and duodenal ulcers,

12. Recurrent nausea and vomiting, chronic gastrointestinal disease or intestinal resection that prevents proper absorption,

13. Severe psychiatric illness (including but not limited to manic psychiatric disorder, schizophrenia, bipolar disorder, major depression requiring hospitalization) or social disturbance that limits eligibility for examination,

14. History of other malignancy within the last 5 years (except properly treated basalioma or squamous cell carcinoma of the skin and in situ carcinoma),

15. History of allergic reaction to phenelzine, selegiline or other monoamine oxidase inhibitors (MAOIs) biological agents or similar chemical ingredients,

16. History of allergic reaction to docetaxel therapy or its ingredients,

17. Significant peripheral neuropathy (≥ Grade 2),

18. Selegiline is contra-indicated for concomitant use with:

1. Certain narcotic analgesics (eg. pethidine),

2. Drugs that enhance the sympathetic nervous system,

3. Other MAO inhibitors,

4. Drugs similar to MAO inhibitors,

5. Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs),

6. Tricyclic antidepressants.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

E-Group ICT Software Informatikai Zrt.

UNKNOWN

Sponsor Role: collaborator

László Mangel

OTHER

Sponsor Role: lead

Responsible Party

László Mangel

Prof MD

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

University of Pécs, Clinical Centre, Department of Oncotherapy

Pécs, Baranya, Hungary

Site Status: RECRUITING

Countries

Hungary

Central Contacts

László Mangel, Prof. MD

Role: CONTACT

mangel.laszlo@pte.hu

+36-72-536-480

Facility Contacts

László Mangel, Prof. MD

Role: primary

mangel.laszlo@pte.hu

+36-72-536-480

Other Identifiers

2019-002685-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

MAO201901

Identifier Type: -

Identifier Source: org_study_id